Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy
Diabetes · 2023
DOI: 10.2337/db22-0515 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2023. Verfasst von Stavroula Dionysopoulou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Medicine, University of Crete, Heraklion, Crete, Greece. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Diabetes Mellitus. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Univeristy of Crete.
Abstract (Originalsprache)
NADPH oxidases (NOXs) are major players in generating reactive oxygen species (ROS) and are implicated in various neurodegenerative ocular pathologies. The aim of this study was to investigate the role of a NOX4 inhibitor (GLX7013114) in two in vivo, experimental streptozotocin (STZ) paradigms depicting the early events of diabetic retinopathy (DR). Animals in the diabetic treated group received GLX7013114 topically (20 μL/eye, 10 mg/mL, once daily) for 14 days (paradigm A: preventive) and 7 days (paradigm B: treated) at 48 h and 4 weeks after STZ injection, respectively. Several methodologies were used (immunohistochemistry, Western blot, real-time PCR, ELISA, pattern electroretinography [PERG]) to assess the diabetes-induced early events of DR, namely oxidative stress, neurodegeneration, and neuroinflammation, and the effect of GLX7013114 on the diabetic insults. GLX7013114, administered as eye drops (paradigms A and B), was beneficial in treating the oxidative nitrative stress, activation of caspase-3 and micro- and macroglia, and attenuation of neuronal markers. It also attenuated the diabetes-induced increase in vascular endothelial growth factor, Evans blue dye leakage, and proinflammatory cytokine (TNF-α protein, IL-1β/IL-6 mRNA) levels. PERG amplitude values suggested that GLX7013114 protected retinal ganglion cell function (paradigm B). This study provides new findings regarding the pharmacological profile of the novel NOX4 inhibitor GLX7013114 as a promising therapeutic candidate for the treatment of the early stage of DR. Article Highlights NADPH oxidases (NOXs) are implicated in the early pathological events of diabetic retinopathy (DR). The NOX4 inhibitor GLX7013114, topically administered, reduced oxidative damage and apoptosis in the rat streptozotocin model of DR. GLX7013114 protected retinal neurons and retinal ganglion cell function and reduced the expression of pro-inflammatory cytokines in the diabetic retina. GLX7013114 diminished the diabetes-induced increase in vascular endothelial growth factor levels and Evans blue dye leakage in retinal tissue. GLX7013114 exhibits neuroprotective, anti-inflammatory, and vasculoprotective properties that suggest it may have a role as a putative therapeutic for the early events of DR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, School of Medicine, University of Crete, Heraklion, Crete, Greece.
- Glucox Biotech AB, Stockholm, Sweden.
- University of Catania, Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, Catania, Italy.
- Uppsala University, Faculty of Pharmacy, Uppsala, Sweden.
- Laboratory of Rheumatology, Autoimmunity and Inflammation, School of Medicine, University of Crete, Heraklion, Crete, Greece.
- Laboratory of Immune Regulation and Tolerance, School of Medicine, University of Crete, Heraklion, Crete, Greece.
ORCID-Profile: Kyriaki Thermos
Förderung
- Univeristy of Crete
Zitieren
APA
Dionysopoulou, S., Wikstrom, P., Bucolo, C., Romano, G. L., Micale, V., Svensson, R., Spyridakos, D., Mastrodimou, N., Georgakis, S., Verginis, P., Walum, E., & Thermos, K. (2023). Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy. Diabetes. https://doi.org/10.2337/db22-0515
Vancouver
Dionysopoulou S, Wikstrom P, Bucolo C, Romano GL, Micale V, Svensson R, et al. Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy. Diabetes. 2023. doi:10.2337/db22-0515
BibTeX
@article{Dionysopoulou2023,
author = {Dionysopoulou, Stavroula and Wikstrom, Per and Bucolo, Claudio and Romano, Giovanni Luca and Micale, Vincenzo and Svensson, Richard and Spyridakos, Dimitris and Mastrodimou, Niki and Georgakis, Spiros and Verginis, Panayotis and Walum, Erik and Thermos, Kyriaki},
title = {Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy},
journal = {Diabetes},
year = {2023},
doi = {10.2337/db22-0515}
}
EUVIMED